Considerations in the development of circulating tumor cell technology for clinical use

[1]  D. Haber,et al.  Circulating tumor cells: a window into cancer biology and metastasis. , 2010, Current opinion in genetics & development.

[2]  D. Noh,et al.  Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. , 2011, Japanese journal of clinical oncology.

[3]  David B. Lee.  Foundation for the National Institutes of Health: Facilitating the Development and Qualification of Alzheimer's Disease Biomarkers Through Novel Public-Private Partnerships , 2009, Alzheimer's & Dementia.

[4]  J. A. Lorente Acosta,et al.  Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[5]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[7]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Mavroudis,et al.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Pantel,et al.  Circulating epithelial cells in patients with benign colon diseases. , 2012, Clinical chemistry.

[10]  T. Fehm,et al.  HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.

[11]  Leon W.M.M. Terstappen,et al.  Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[12]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Sotiriou,et al.  HER2-Positive Circulating Tumor Cells in Breast Cancer , 2011, PloS one.

[14]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[15]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[16]  Caroline Dive,et al.  Circulating tumor cells as a window on metastasis biology in lung cancer. , 2011, The American journal of pathology.

[17]  Lawrence D. True,et al.  Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.

[18]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[19]  B. Lilly,et al.  Differential gene expression in a coculture model of angiogenesis reveals modulation of select pathways and a role for Notch signaling. , 2009, Physiological genomics.

[20]  K. Pienta,et al.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. , 2003, Cancer research.

[21]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[22]  E. Lianidou,et al.  Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. , 2011, Clinical chemistry.

[23]  V. Chiarion-Sileni,et al.  Circulating tumor cells detection and evaluation of their apoptotic status in patients with localized breast cancer before and after surgery. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Reyal,et al.  Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. , 2011, Annals of Oncology.

[25]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[26]  K. Pantel,et al.  Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells , 2012, Clinical Cancer Research.

[27]  Mehmet Toner,et al.  Circulating tumor cells: approaches to isolation and characterization , 2011, The Journal of cell biology.

[28]  T. Ward,et al.  Circulating Tumor Cells, Enumeration and Beyond , 2010, Cancers.

[29]  Paul I. Okagbare,et al.  Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. , 2008, Journal of the American Chemical Society.

[30]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[31]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[32]  B. Molnár,et al.  Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[34]  Daniel F. Hayes,et al.  Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer? , 2008, Clinical Cancer Research.

[35]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[36]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[37]  E. Lianidou.  Circulating tumor cells--new challenges ahead. , 2012, Clinical chemistry.

[38]  Yvonne A. Evrard,et al.  Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells , 2010, Clinical Cancer Research.

[39]  H. Scher,et al.  Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[40]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[41]  A. Semjonow,et al.  BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood , 2010, Clinical Cancer Research.

[42]  A W Partin,et al.  Identification and characterization of circulating prostate carcinoma cells , 2000, Cancer.

[43]  K. Isselbacher,et al.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip , 2010, Proceedings of the National Academy of Sciences.

[44]  N. Nelson.  Circulating tumor cells: will they be clinically useful? , 2010, Journal of the National Cancer Institute.

[45]  L. Kiesel,et al.  HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.

[46]  José Antonio Lorente Acosta,et al.  Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours. , 2009 .

[47]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[48]  A. Semjonow,et al.  BRCA1 loss pre-existing in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood , 2010 .

[49]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[50]  J. Dancey,et al.  A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment , 2009, Journal of the National Cancer Institute.

[51]  Paraskevi Giannakakou,et al.  Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device , 2012, PloS one.

[52]  J. Nemunaitis,et al.  Circulating Tumor Cells in Melanoma: A Review of the Literature and Description of a Novel Technique , 2008, Proceedings.

[53]  M. Naoe,et al.  Detection of circulating urothelial cancer cells in the blood using the CellSearch System , 2007, Cancer.

[54]  Stephen Little,et al.  The impact of FDA guidance on pharmacogenomic data submissions on drug development. , 2005, IDrugs : the investigational drugs journal.

[55]  F. Tanaka,et al.  Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. , 2009, The Annals of thoracic surgery.

[56]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[57]  H. Scher,et al.  TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. , 2011, European urology.

[58]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[59]  S. Minner,et al.  Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. , 2012, European urology.

[60]  M. Keeney,et al.  Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic , 2009, Journal of oncology.

[61]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[62]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Tompkins,et al.  Abstract 1136: Detection and characterization of circulating tumor cells in localized and metastatic prostate cancer patients using CTC-Chip microfluidic technology , 2010 .

[64]  L. Frati,et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.